| abstract |
The present invention provides pharmaceuticalncompositions comprising as an active ingredient a selective SGLT1ninhibitor (e.g., an SGLT1 inhibitor substantially showing nonGLUT2 and/or GLUT5 inhibitory effect), which have a wider rangenof inhibitory effect on carbohydrate absorption and anhypoglycemic effect caused by fructose ingestion at regular dietsnand therefore can exhibit a marked hypoglycemic effect, and whichnare suitable as agents for the prevention or treatment of diseasesnassociated with hyperglycemia (e.g., diabetes, impaired glucosentolerance, diabetic complications, obesity). |